SOURCE: Pacific Dynasty Consultants / Issues Investment Alert On (NASDAQ: KERX), (NASDAQ: ARNA), (NASDAQ: VVUS), (NASDAQ: BIDU), (NYSE: SNE) Is announcing Investment Highlights on Keryx Biopharmaceuticals (NASDAQ: KERX), Arena Pharmaceuticals, Inc. (NASDAQ: ARNA), VIVUS, Inc. (NASDAQ: VVUS),, (NASDAQ: BIDU)

NEW YORK, January 29, 2013 – Keryx Biopharmaceuticals (NASDAQ: KERX) shares climbed 18.04% to $7.15 in pre-market hour after the company yesterday announced successful top-line results from the long-term Phase 3 study of Zerenex™ (ferric citrate), the Company's ferric iron-based phosphate binder drug candidate, for the treatment of elevated serum phosphorus levels, or hyperphosphatemia, in patients with end-stage renal disease (ESRD) on dialysis.  In this study, Zerenex met the study's primary endpoint, described below, demonstrating a highly statistically significant change in serum phosphorus versus placebo over the four-week Efficacy Assessment Period of the study.

In addition, Zerenex met the key secondary endpoints of increasing ferritin and transferrin saturation (TSAT) and reducing the use of intravenous (IV) iron and erythropoiesis-stimulating agents (ESAs) versus the active control over the 52-week Safety Assessment Period of the study.

Will KERX Move Higher After Today’s Sudden Selling Activities? Don’t Miss The Free Trend Analysis here


Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) shares fell 0.12% to $8.55 in the pre-market hour after ARNA’s stock has been reiterated by TheStreet Ratings as a sell with a ratings score of D- .

The company recently claimed that an advisory committee for the EMA (European Medicines Agency) is trying to find out more about Belviq's safety profile - specifically regarding its supposed "heart valve issues" and "psychiatric side effects" on top of the tumors that were found during animal studies.

How Should Investors Trade ARNA After The Recent Momentum, Find Out Here


VIVUS, Inc. (NASDAQ: VVUS), on Jan. 7, said prescriptions for obesity drug Qsymia, its main product, rose nearly 68% in the month ended December 21 compared with the preceding four weeks, well above industry forecasts. The drugmaker said it shipped 12,978 prescriptions of Qsymia in the latest period, up from 7,749 in the four weeks ended November 23. New Qsymia prescriptions totaled 5,229 in the latest period.

Get Free Special Trend Analysis On VVUS Here, Inc. (ADR) (NASDAQ: BIDU) shares gained 1% to $112.44 in the pre-market hour. The company announced that it will report its financial results for the fourth quarter and fiscal year ended December 31, 2012, after the U.S. market closes on February 4, 2013. Baidu's management will hold an earnings conference call at 8:00 PM on February 4, 2013, U.S. Eastern Time (9:00 AM on February 5, 2013, Beijing/Hong Kong Time).

Get Free Special Trend Analysis On BIDU Here 


Sony Corporation (ADR) (NYSE: SNE) shares climbed 0.26% to $15.16 in the pre-market hour. Sony Corporation and Nintendo Co are expected to come back to life as China is thinking of removing a decade old embargo on the sales of game consoles produced by Sony Corp, according to a news published in China Daily recently.

Additionally, Reuters on Jan. 24 reported that a Japanese state-backed fund wants a Nissan Motor Co Ltd and NEC Corp joint venture to buy Sony Corp's lithium-ion battery unit to prevent rivals in China and Taiwan from getting its technology as the Tokyo TV maker looks to offload non-core businesses, the Daily Yomiuri reported.

Get Free Special Trend Analysis On SNE Here 


About has a finger on the pulse of many sectors including renewable energy, oil, pharma, mining, finance, and healthcare. Our in depth research and analysis of NASDAQ, OTCBB, Pink Sheets, and NYSE has yielded considerable gains for our subscribers.

Our to-the-minute reports and alerts coupled with breaking news, analysis, investment strategies, and FREE subscription email services contribute to our role as one of the leading investor relations marketing firms.



The assembled information disseminated by is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. does expect that investors will buy and sell securities based on information assembled and presented in PLEASE always do your own due diligence, and consult your financial advisor.



Pacific Dynasty Consultants Inc.

2637 E Atlantic Blvd #22611 Pompano Beach, FL 33062